What is the recommended first‑line management for generalized anxiety disorder?

First-Line Management of Generalized Anxiety Disorder

Start with either escitalopram 10 mg daily or sertraline 25–50 mg daily as first-line pharmacotherapy, combined with individual cognitive-behavioral therapy (12–20 sessions over 3–4 months) for optimal outcomes. 1, 2

Pharmacological First-Line Treatment

Preferred SSRIs

• Escitalopram and sertraline are the top-tier first-line agents due to their established efficacy, favorable side effect profiles, lowest potential for drug-drug interactions, and minimal discontinuation symptoms compared to other SSRIs. 1, 2
• Begin with a low dose—escitalopram 10 mg daily or sertraline 25–50 mg daily—to minimize initial anxiety or agitation that can occur with SSRI initiation. 1, 2
• Titrate by 5–10 mg increments for escitalopram or 25–50 mg increments for sertraline every 1–2 weeks as tolerated, targeting escitalopram 10–20 mg/day and sertraline 50–200 mg/day. 1

Expected Timeline for Response

• Statistically significant improvement may begin by week 2, with clinically significant improvement expected by week 6, and maximal therapeutic benefit achieved by week 12 or later. 1, 2
• Do not abandon treatment prematurely—full response may take 12+ weeks, and patience in dose escalation is crucial for optimal outcomes. 1

Alternative First-Line SSRIs (Second-Tier)

• Paroxetine (20–60 mg/day) and fluvoxamine are equally effective but carry higher risks of discontinuation symptoms and drug-drug interactions, so reserve them for when escitalopram or sertraline fail. 1

SNRI Alternative

• Venlafaxine extended-release (75–225 mg/day) is an effective alternative when SSRIs are ineffective or not tolerated after an adequate 8–12 week trial at therapeutic doses. 1, 2
• Venlafaxine requires blood pressure monitoring due to risk of sustained hypertension. 1
• Duloxetine (60–120 mg/day) has demonstrated efficacy in GAD and offers additional benefits for patients with comorbid pain conditions. 1

Cognitive-Behavioral Therapy

CBT as Essential Component

• Individual CBT (12–20 sessions over 3–4 months) should be provided alongside medication, as combined treatment yields superior outcomes compared to medication or therapy alone. 1, 2
• Individual CBT is prioritized over group therapy due to superior clinical and cost-effectiveness, with large effect sizes for GAD (Hedges g = 1.01). 1
• CBT should include psychoeducation on anxiety, cognitive restructuring to challenge distortions, relaxation techniques (breathing, progressive muscle relaxation), and gradual exposure when appropriate. 1

Alternative CBT Delivery

• If face-to-face individual CBT is unavailable or declined by the patient, self-help CBT with professional support (approximately 9 sessions over 3–4 months) is a viable alternative. 3, 1

Treatment Algorithm for Inadequate Response

After 8–12 Weeks at Therapeutic Dose

• Switch to a different SSRI (e.g., sertraline to escitalopram or vice versa) if inadequate response after 8–12 weeks at therapeutic doses with good adherence. 1
• Add individual CBT if not already implemented, as combining medication with CBT provides superior outcomes. 1, 2
• Consider switching to venlafaxine XR (75–225 mg/day) if multiple SSRIs have failed. 1

Second-Line Medications

• Pregabalin can be considered when first-line treatments are ineffective or not tolerated, particularly for patients with comorbid pain conditions. 1

Monitoring and Maintenance

Assessment and Follow-Up

• Assess response using standardized anxiety rating scales (e.g., GAD-7, HAM-A) within 4–6 weeks of reaching therapeutic dose. 1, 2
• Monitor for common SSRI/SNRI side effects: nausea, sexual dysfunction, headache, insomnia, dry mouth, diarrhea, somnolence, and dizziness—most emerge within the first few weeks and typically resolve with continued treatment. 1
• Monitor closely for suicidal thinking and behavior, especially in patients ≤24 years during the first months and following dose adjustments, with a pooled risk difference of 0.7% versus placebo. 1

Treatment Duration

• Continue effective medication for a minimum of 9–12 months after achieving remission to prevent relapse, with reassessment monthly until symptoms stabilize, then every 3 months. 1
• For recurrent episodes, maintaining SSRI treatment on a long-term or indefinite basis is advised to reduce relapse risk. 1

Medications to Avoid

Benzodiazepines

• Benzodiazepines should be reserved for short-term use only (days to a few weeks) due to risks of dependence, tolerance, cognitive impairment, and withdrawal—they are not recommended as first-line or long-term therapy. 1, 2
• Avoid benzodiazepines entirely in patients with substance use history, respiratory disorders, or elderly patients. 2

Beta-Blockers

• Beta-blockers (atenolol, propranolol) are deprecated by Canadian guidelines for GAD based on negative evidence and should not be prescribed. 3, 1

Adjunctive Non-Pharmacological Interventions

• Structured physical activity and regular cardiovascular exercise provide moderate to large reduction in anxiety symptoms and should be recommended alongside primary treatment. 1
• Breathing techniques, progressive muscle relaxation, grounding strategies, mindfulness, and visualization are useful adjunctive anxiety management strategies. 1
• Provide psychoeducation to family members about anxiety symptoms and treatment, and consider referral for treatment for parents or caregivers who struggle with anxiety themselves. 1

Critical Pitfalls to Avoid

• Do not commence pharmacotherapy before trialing evidence-based non-pharmacologic interventions such as CBT, which provide more durable benefits. 1
• Do not escalate SSRI doses too quickly—allow 1–2 weeks between increases to assess tolerability and avoid overshooting the therapeutic window. 1
• Taper SSRIs gradually when discontinuing to avoid discontinuation syndrome (dizziness, fatigue, nausea, sensory disturbances, anxiety), particularly with shorter half-life SSRIs like sertraline and paroxetine. 1, 2
• Do not overlook functional impairment assessment—significant impairment may justify earlier or more intensive treatment despite low symptom scores. 1
• Patients with anxiety pathology commonly avoid follow-through on referrals, so proactively assess and address barriers to treatment adherence. 1